Article

Pharmaceutical Executive

Johnson & Johnson, Sanofi Top the 2017 Good Pharma Scorecard

Author(s):

The 2017 GPS ranking evaluates clinical trial registration, results reporting, clinical study report synopsis sharing, and journal article publication rates for new drugs approved by the Food and Drug Administration in 2014 that were sponsored by large drug companies.

The second publication of Bioethics International's Good Pharma Scorecard, an annual index ranking large pharmaceutical companies and new drugs on their clinical trial transparency, was published in BMJ Open. 

Johnson & Johnson and Sanofi, two of eleven ranked companies achieved the highest overall clinical trial transparency scores, both scoring 100%. AbbVie, Celgene, Merck, and Astra Zeneca all scored at or above the industry median.  

“We created the GPS to help advance trustworthiness and ethics in the pharmaceutical sector, by setting clear ethics standards and benchmarking the performance of companies against those standards every year,” said Jennifer E. Miller, Ph.D., founder of Bioethics International and lead author on the paper. “This year’s Scorecard shows clear corporate leaders in clinical trial transparency and industry improvement on several metrics. We hope this improvement continues year after year, because clinical trial transparency is critical for advancing innovation, respect for trial participants, and patient health.”

The 2017 GPS ranking evaluates clinical trial registration, results reporting, clinical study report synopsis sharing, and journal article publication rates for new drugs approved by the Food and Drug Administration  in 2014 that were sponsored by large drug companies. 

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Related Videos
Gen Li
Robert Lisicki
Gen Li
Gen Li
Dr. Ben Zeskind
Gen Li
Dr. Ben Zeskind
Gen Li
Related Content